Abstract: In a process for dehydrating 5-hydroxy-11a-chlorotetracycline-6,12-hemiketal to 5-hydroxy-6-demethyl-6-desoxy-6-methylene-11a-chlorotetracycline, utilizing an acid which is not decomposable by water, formic acid serves as a solvent free from chlorinated hydrocarbons.

Abstract: Compounds of the formula ##STR1## the pharmaceutically acceptable salts thereof, wherein Q and R.sup.1 are as defined below, and novel carboxylic acid and acid halide intermediates used in the synthesis of such compounds. The compounds of formula I are inhibitors of acyl coenzyme A: cholesterol acyltransferase (ACAT) and are useful as hypolipidemic and antiatherosclerosis agents.

Abstract: Compounds of the formula ##STR1## and pharmaceutically acceptable salts and prodrugs thereof, wherein X.sup.1, Ar, X, Y.sup.1, R.sup.1, R.sup.2, R.sup.3, R.sup.5 and n are defined below, which are inhibitors of the production of leukotrienes and/or blockers of leukotriene receptors, methods for preparing said compounds and intermediates useful in the preparation thereof, pharmaceutical compositions thereof methods of treatment therewith. The compounds of the above formula are useful in the prevention or treatment of asthma, arthritis, psoriasis, ulcers, myocardial infarction and related diseases in mammals.

Abstract: Compounds of the formula ##STR1## and the pharmaceutically acceptable salts thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, m, X and Q are as defined below, and novel intermediates used in the synthesis of such compounds. The compounds of formula I are inhibitors of acyl coenzyme A: cholesterol acyltransferase (ACAT) and are useful as hypolipidemic and natiatherosclerosis agents.

Abstract: Compounds of the formula ##STR1## the pharmaceutically acceptable salts thereof wherein R.sup.2, R.sup.3, R.sup.4, m, X and Q are as defined below, and novel intermediates used in the synthesis of such compounds. The compounds of formula I are inhibitors of acyl coenzyme A: cholesterol acyltransferase (ACAT) and are useful as hypolipidemic and antiatherosclerosis agents.

Abstract: Certain indoline derivatives of the formula I: ##STR1## wherein the variables Y, A, R.sub.1, R.sub.4 and n have the definitions set forth in the disclosure, have the ability to inhibit the 5-lipoxygenase enzyme. These compounds are useful in the treatment or alleviation of inflammatory diseases, allergic conditions and cardiovascular diseases in mammals and as the active ingredient in pharmaceutical compositions for treating such conditions.

Abstract: Processes, and intermediates, for use in preparing the compound of the formula ##STR1## The compounds of formula II are useful in the preparation of cis (+) N-trifluoromethylsulfonyl-3-[4-hydroxy-6-ArO-chroman-3-ylmethyl]-4-methoxy aniline compounds wherein Ar is defined below. The cis (+) N-trifluoromethylsulfonyl-3-[4-hydroxy-6-ArO-chroman-3-ylmethyl]-4-methoxy aniline compounds are useful for inhibiting the production of leukotrienes and/or blocking leukotriene receptors and in the prevention or treatment of asthma, arthritis, psoriasis, ulcers, myocardial infarction and related disease states in mammals.

Abstract: The present invention relates to novel acyclic ethylenediamine derivatives of nitrogen containing heterocyclic compounds, and specifically, to compounds of the formula ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are defined as in the specification. It also relates to novel intermediates used in the synthesis of such derivatives.Compounds of the formula I and their pharmaceutically acceptable salts are useful in the treatment of inflammatory and central nervous system disorders, as well as other disorders.

Abstract: This invention relates to compounds of the formula ##STR1## wherein Q, Z, D, E, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are defined as below, and the pharmaceutically acceptable salts thereof are disclosed. The compounds are useful as antihypertensive agents.

Abstract: Aqueous solutions for treating inflammations of the eye, comprising: from about 0.03-3 weight percent of piroxicam; an effective amount of a buffer; from about 0 to about 1 weight percent of a wetting agent; from about 0 to about 5 weight percent of a pH adjusting agent; from about 0 to about 5 weight percent of a tonicity agent; an effective amount of a preservative; from about 0 to about 3 weight percent of a demulcent polymer; from about 0 to about 40 weight percent of a complexing agent; and from about 0 to about 0.1 weight percent of a stabilizer; and having a pH between about 7 and about 10.

Abstract: Compounds of the formula ##STR1## wherein R.sup.21 and R.sup.22 are as defined in the specification which are intermediates useful in the preparation of compounds of the formula ##STR2## and the pharmaceutically acceptable salts thereof, wherein Q and R.sup.1 are as defined in the specification. The compounds of formula I are inhibitors of acyl coenzyme A: cholesterol acyltransferase (ACAT) and are useful as hypolipidemic and antiatherosclerosis agents.

Abstract: A process for preparing the compound of the formula ##STR1## which comprises treating a compound of the formula ##STR2## wherein R.sup.2 is hydrogen, CN or CO.sub.2 R.sup.1 and R.sup.1 is hydrogen or (C.sub.1 -C.sub.6)alkyl with a reducing agent with the proviso that when R.sup.2 is CN or CO.sub.2 R.sup.1 and R.sup.1 is (C.sub.1 -C.sub.6)alkyl the product of the reduction is heated with an acid. Compounds of formula II wherein R.sup.2 is CN or CO.sub.2 R.sup.1 and R.sup.1 is (C.sub.1 -C.sub.6)alkyl or R.sup.2 is hydrogen and R.sup.1 is (C.sub.1 -C.sub.6)alkyl or hydrogen. The compound of formula VII R.sup.1 is (C.sub.1 -C.sub.6)alkyl. The compound of formula III. The compound of formula I is useful in the treatment of psychotic disorders.

Abstract: Compounds of the formula ##STR1## wherein R, Y and R.sup.1 are as defined in the specification. These compounds are muscarinic receptor antagonists which are selective for smooth muscle muscarinic sites over cardiac muscarinic sites, and are useful in the treatment of diseases associated with altered motility on tone of smooth muscle, including irritable bowel syndrome, diverticular disease, urinary incontinence, oesophageal achalasia and chronic obstructive airways disease.

Abstract: Compounds of the formula ##STR1## wherein one of A, B, D and E is N and the remaining three atoms are C; R.sup.1 and R.sup.2 are independently selected from hydrogen and C.sub.1 to C.sub.6 alkyl; and R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are independently selected from hydrogen, halogen, hydroxy, C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.8 alkoxy, phenyl-C.sub.1 -C.sub.6 alkoxy, phenoxy, --NR.sup.7 R.sup.8 wherein R.sup.7 and R.sup.8 are independently selected from hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkanoyl, and COOR.sup.9 wherein R.sup.9 is hydrogen or C.sub.1 -C.sub.6 alkyl, cyano, COOR.sup.10 wherein R.sup.10 is hydrogen or C.sub.1 -C.sub.6 alkyl, and CONR.sup.11 R.sup.12 where R.sup.11 and R.sup.12 are independently selected from hydrogen and C.sub.1 -C.sub.6 alkyl, and the pharmaceutically acceptable salts thereof. The compounds are useful psychotherapeutics and may be used in treating obesity, depression and disorders wherein aggression is a symptom.

Abstract: A disposable, low cost autotransfusion device for suction assisted drainage of fluids from a body cavity of a patient, purification and collection of the desired liquids within said fluids, primarily blood, for reinfusion into said patients said device comprising a) a housing comprising an accumulation chamber, inlet means, in fluid connection with said cavity, through which said fluids enter the chamber, the discharge stem of which terminates in a one-way valve to prevent backflow of gases from said chamber to said cavity in the event the pressure within the cavity becomes less than that within the chamber, filter means to remove unwanted materials, such as debris, from the draining fluids, disposed between said one-way valve and inlet stem and the chamber, first outlet means in fluid connection with a vacuum source through which suction is applied to said chamber and second outlet means in fluid connection with b) an autotransfusion bag comprising outlet means comprising a break seal for connection to the p

Abstract: A method for producing a bifocal contact lens comprising, in combination, the steps of generating a first, concave surface on a first side of a lens blank eccentrically mounted in concave surface cutting means, wherein the center of curvature of the concave surface lies on an axis offset from the optical center axis of the lens blank by a prism offset distance; generating a second, convex surface on the second side of the lens blank, wherein the center of curvature of the convex surface lies on the optical center axis of the lens blank; generating a third, convex surface on the second side of the lens blank eccentrically mounted in convex surface cutting means, wherein the center of curvature of the third, convex surface is coaxial with the second, convex surface; trimming the first, concave surface to form a fourth, concave surface on the first side of the lens blank the curvature of the fourth surface corresponding to the base curve; and finishing the lens by known methods.

Abstract: An article useful in the suction-assisted removal of fluids, including gases, such as air, and liquids, such as blood, from a body cavity which will prevent flow of gases therethrough into said cavity without the intervention of any liquid seals, in the event the pressure within said cavity becomes negative relative to the pressure at the discharge end of said article comprising a cap assembly, for fluid connection to said cavity and an accumulation chamber, for applying a controlled suction to said cavity, said assembly comprising a horizontal wall comprising at its periphery and normal thereto an annular wall for attachment to a liquid collection container surrounding said accumulation chamber; inlet means in fluid connection with said cavity, and, as desired, a liquid accumulation chamber or the atmosphere, through which said fluids may pass when the pressure within the cavity is greater than at the discharge end of said means; first one-way valve means associated with the discharge end of said inlet means

Abstract: An article useful in laser-effected surgery and therapy on humans and animals which reduces or eliminates undesired exposure of said humans, animals and other articles to said lasers comprising(a) a first member proximal to the laser source comprising a xerogel comprising at least one hydrophilic water-insoluble polymer;(b) a second, backing member;(c) water;wherein, if desired, said xeogel layer further comprises at least one additive selected from the group consisting of pharmaceutically acceptable salts, colorants, including pigments, and medications.The invention further comprises an article comprising at least one metallic layer disposed between said xerogel and backing members the proximal surface of said metallic layer being reflective or non-reflective of the laser beams as required.If desired adhesives may also be disposed between the layers of the article and/or between the article and the surface to be protected.

Abstract: A foam producing device for the alternative dispensing of foams or liquids comprising a porous element a partially gas permeable wall, a gas distributing plenum a gas entry port in fluid connection with said plenum; a second wall opposite the outer surface of said gas permeable wall; a mixing chamber comprising at one end, the proximal end, a small annular opening between said gas permeable and second wall, comprising an orifice for the uniform distribution of foamable liquids therethrough into said chamber and at the distal end an exit port for the discharge of foams or liquids from said chamber said chamber being tapered or not, as required; a liquid distribution plenum for the uniform distribution of said foamable liquids to said orifice and a liquid entry port in fluid connection, through a conduit with said plenum wherein said plenum and a source of foamable liquid are in fluid connection through a conduit therebetween; with the proviso that only the portion of said gas permeable wall between said orific

Abstract: A retractable hypodermic needle & syringe article comprising barrel means comprising means to receive and removably restrain a hypodermic needle-containing assembly for dispensing liquids, plunger means to force the liquids through the needle and a hypodermic needle-containing hub adapted to be removably held at the distal end of the barrel said plunger and hub comprising complementary means to engage, after final use of the article, and retract said hypodermic needle-containing hub into the barrel from which is cannot be reextended for further use wherein the plunger further comprises means to cause the needle-containing hub to assume an angled position relative to the longitudinal axis of the plunger when the hub has been retracted into the barrel.